C52H48N4O10Sn2, triclinic, P1̄ (no. 2), a = 8.4845(1) Å, b = 9.2814(1) Å, c = 15.5517(2) Å, α = 83.005(1)°, β = 81.918(1)°, γ = 74.690(1)°, V = 1164.87(2) Å3, Z = 1, Rgt(F) = 0.0173, wRref(F2) = 0.0453, T = 100(2) K
The title compound, [Sn(C4H9)2(C6H5COO)2], was synthesized in order to study the interaction between...
The title compound, [Sn(C4H9)2(C6H5COO)2], was synthesized in order to study the interaction between...
C28H26CuN2O9, monoclinic, C2/c, a = 12.3146(11) Å, b = 11.1769(10) Å, c = 19.3856(17) Å, β = 101.012...
C84H52Cl8F16O10Sn4, triclinic, P1̄ (no. 2), a = 11.2999(9) Å, b = 14.1471(11) Å, c = 15.2378(12) Å, ...
C12H14N7O9Sm, monoclinic, P21/c (no. 14), a = 16.770(3) Å, b = 7.7185(16) Å, c = 15.165(3) Å, β = 10...
C24H17N2O10S2Sm, triclinic, P1̅ (no. 2), a = 10.135(5) Å, b = 10.697(5) Å, c = 11.823(7) Å, ɑ = 94.6...
In the title molecule, [Sn(C7H6Cl)2(C6H4NO2)2(H2O)], the O atoms of the two chelating nicotinate gro...
The crystal structure of the title compound, {Ph 3Sn[O 2CC 6H 4(N=N(C 6H 3-4-OH-5-CHO))-o]OH 2}, rev...
C52H32F4N6O14Tb2, triclinic, P1̅ (no. 2), a = 10.745(2) Å, b = 10.993(2) Å, c = 11.141(2) Å, α = ...
C16H25FN2O4S2Sn, monoclinic, P21/n (no. 14), a = 11.2227(1) Å, b = 12.6793(1) Å, c = 13.8731(1) Å, β...
C24H22N9NdO17, triclinic, P1̅ (no. 2), a = 7.6445(15) Å, b = 7.9378(16) Å, c = 25.741(5) Å, α = 9...
C34H34N10O9Zn, monoclinic, P1̄ (no. 2), a = 10.1188(13) Å, b = 12.9297(16) Å, c = 15.0668(19) Å, α =...
C54H50Cl4O2P2Sn, triclinic, P1̄ (no. 2), a = 10.6360(2) Å, b = 10.8406(2) Å, c = 12.5727(2) Å, α = 9...
C62H80Mn2N16O18, triclinic, P1̅ (no. 2), a = 11.3232(10) Å, b = 12.879(2) Å, c = 13.035(2) Å, α = 84...
C30H44N2O4Sn2, monoclinic, P21/c, a = 8.8810(8) Å, b = 16.8999(13) Å, c = 10.5705(10) Å, β = 92.0460...
The title compound, [Sn(C4H9)2(C6H5COO)2], was synthesized in order to study the interaction between...
The title compound, [Sn(C4H9)2(C6H5COO)2], was synthesized in order to study the interaction between...
C28H26CuN2O9, monoclinic, C2/c, a = 12.3146(11) Å, b = 11.1769(10) Å, c = 19.3856(17) Å, β = 101.012...
C84H52Cl8F16O10Sn4, triclinic, P1̄ (no. 2), a = 11.2999(9) Å, b = 14.1471(11) Å, c = 15.2378(12) Å, ...
C12H14N7O9Sm, monoclinic, P21/c (no. 14), a = 16.770(3) Å, b = 7.7185(16) Å, c = 15.165(3) Å, β = 10...
C24H17N2O10S2Sm, triclinic, P1̅ (no. 2), a = 10.135(5) Å, b = 10.697(5) Å, c = 11.823(7) Å, ɑ = 94.6...
In the title molecule, [Sn(C7H6Cl)2(C6H4NO2)2(H2O)], the O atoms of the two chelating nicotinate gro...
The crystal structure of the title compound, {Ph 3Sn[O 2CC 6H 4(N=N(C 6H 3-4-OH-5-CHO))-o]OH 2}, rev...
C52H32F4N6O14Tb2, triclinic, P1̅ (no. 2), a = 10.745(2) Å, b = 10.993(2) Å, c = 11.141(2) Å, α = ...
C16H25FN2O4S2Sn, monoclinic, P21/n (no. 14), a = 11.2227(1) Å, b = 12.6793(1) Å, c = 13.8731(1) Å, β...
C24H22N9NdO17, triclinic, P1̅ (no. 2), a = 7.6445(15) Å, b = 7.9378(16) Å, c = 25.741(5) Å, α = 9...
C34H34N10O9Zn, monoclinic, P1̄ (no. 2), a = 10.1188(13) Å, b = 12.9297(16) Å, c = 15.0668(19) Å, α =...
C54H50Cl4O2P2Sn, triclinic, P1̄ (no. 2), a = 10.6360(2) Å, b = 10.8406(2) Å, c = 12.5727(2) Å, α = 9...
C62H80Mn2N16O18, triclinic, P1̅ (no. 2), a = 11.3232(10) Å, b = 12.879(2) Å, c = 13.035(2) Å, α = 84...
C30H44N2O4Sn2, monoclinic, P21/c, a = 8.8810(8) Å, b = 16.8999(13) Å, c = 10.5705(10) Å, β = 92.0460...
The title compound, [Sn(C4H9)2(C6H5COO)2], was synthesized in order to study the interaction between...
The title compound, [Sn(C4H9)2(C6H5COO)2], was synthesized in order to study the interaction between...
C28H26CuN2O9, monoclinic, C2/c, a = 12.3146(11) Å, b = 11.1769(10) Å, c = 19.3856(17) Å, β = 101.012...